We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$244M
AUM Growth
-$94.8M
Cap. Flow
-$73.9M
Cap. Flow %
-30.28%
Top 10 Hldgs %
68.7%
Holding
38
New
11
Increased
8
Reduced
2
Closed
17

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$21.9M
2
ABBV icon
AbbVie
ABBV
+$18.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
4
AMGN icon
Amgen
AMGN
+$11.3M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$30.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$29.7M
3
A icon
Agilent Technologies
A
+$17.9M
4
LEGN icon
Legend Biotech
LEGN
+$15.9M
5
LLY icon
Eli Lilly
LLY
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
1
Regeneron Pharmaceuticals
REGN
$70.5B
$22.4M 9.19%
31,500
+17,024
+118% +$14.3M
JNJ icon
2
Johnson & Johnson
JNJ
$599B
$20.5M 8.39%
+141,572
New +$21.9M
RPRX icon
3
Royalty Pharma
RPRX
$25.4B
$19.5M 8%
764,859
+100,000
+15% +$2.65M
ABBV icon
4
AbbVie
ABBV
$448B
$18.1M 7.43%
+101,996
New +$18.8M
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.81B
$17.1M 7.01%
406,803
+120,000
+42% +$5.95M
BBIO icon
6
BridgeBio Pharma
BBIO
$15.8B
$15.4M 6.3%
560,344
+163,956
+41% +$4.24M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.78B
$15.1M 6.19%
124,256
+40,500
+48% +$4.96M
INSM icon
8
Insmed
INSM
$23.2B
$14.6M 5.97%
210,884
-5,000
-2% -$360K
TEVA icon
9
Teva Pharmaceuticals
TEVA
$36.1B
$12.9M 5.28%
+584,883
New +$10.6M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.05B
$12.1M 4.94%
628,677
+110,000
+21% +$2.39M
AMGN icon
11
Amgen
AMGN
$197B
$9.93M 4.07%
+38,090
New +$11.3M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.38B
$9.91M 4.06%
301,623
+115,000
+62% +$5.4M
VERA icon
13
Vera Therapeutics
VERA
$2.66B
$8.99M 3.69%
212,696
+39,820
+23% +$1.76M
NAMS icon
14
NewAmsterdam Pharma
NAMS
$3.47B
$8.66M 3.55%
+337,152
New +$7.16M
MRNA icon
15
Moderna
MRNA
$23.6B
$8.21M 3.37%
+197,500
New +$9.44M
PRGO icon
16
Perrigo
PRGO
$1.47B
$7.57M 3.1%
294,517
-263,420
-47% -$6.92M
JANX icon
17
Janux Therapeutics
JANX
$979M
$6.42M 2.63%
+120,000
New +$6.35M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$6.4M 2.62%
+230,000
New +$6.97M
TARS icon
19
Tarsus Pharmaceuticals
TARS
$2.45B
$6.23M 2.55%
+112,500
New +$5.11M
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$2.46M 1.01%
+147,076
New +$2.44M
NMRA icon
21
Neumora Therapeutics
NMRA
$302M
$1.59M 0.65%
+150,000
New +$1.8M
A icon
22
Agilent Technologies
A
$36.8B
– –
-120,485
Closed -$17.9M
ACLX
23
DELISTED
Arcellx
ACLX
– –
-89,863
Closed -$7.5M
AVDL
24
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-385,172
Closed -$5.05M
AXSM icon
25
Axsome Therapeutics
AXSM
$11.4B
– –
-105,767
Closed -$9.51M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Cutter Capital Management held 38 positions worth $244M, down 28% from $339M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Cutter Capital Management withdrew a net $73.9M in Q4 2024, closing 17 positions and reducing 2 holdings. Its most notable exit was Gilead Sciences, an estimated $30.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Cutter Capital Management opened a new position in Johnson & Johnson worth $20.5M.

  • Cutter Capital Management's largest Q4 2024 buy was Johnson & Johnson: 141,572 shares worth $20.5M.
  • Cutter Capital Management added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $14.3M increase.
  • Cutter Capital Management's biggest Q4 2024 reduction was Perrigo, cutting an estimated $6.92M.
  • Cutter Capital Management fully exited Gilead Sciences in Q4 2024, selling an estimated $30.1M.
  • Cutter Capital Management's ten largest holdings make up 69% of its $244M portfolio in Q4 2024.
  • Cutter Capital Management opened 11 new positions and closed 17 in Q4 2024.
  • Cutter Capital Management's portfolio value fell 28% quarter-over-quarter to $244M.

Based on Cutter Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.